FDA approves LIFYORLITM for platinum-resistant ovarian cancer patients

Corcept Therapeutics has chosen Onco360 as the exclusive national pharmacy partner for its newly approved drug, LIFYORLITM (relacorilant). The medication, granted FDA approval on 25 March 2026, treats adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. As of late March, no patients have yet received the drug since its approval came just days earlier. LIFYORLITM is designed for use alongside nab-paclitaxel in patients who have undergone one to three prior treatments, including at least one with bevacizumab. The drug works as a reversible glucocorticoid receptor antagonist, offering a targeted approach for this hard-to-treat cancer.

The FDA's decision followed results from the phase 3 ROSELLA study, which involved 381 participants. The trial met both primary goals: improving progression-free survival and overall survival compared to nab-paclitaxel alone. Common side effects reported in studies included laboratory abnormalities, fatigue, nausea, and reduced blood cell counts. Onco360, based in Louisville, Kentucky, will handle the drug's distribution across the US. Founded in 2003, the company specialises in oncology pharmacy services, supporting hospitals, cancer centres, and manufacturers. As the largest independent oncology pharmacy in the country, it will provide exclusive specialty pharmacy services for LIFYORLITM.

With no post-approval treatment data available yet, LIFYORLITM's real-world impact remains to be seen. The drug's approval offers a new option for patients with limited alternatives, while Onco360's role ensures nationwide access through a dedicated oncology pharmacy network.